• Cierra N Treu, Allison M Stilwell, Eunah Cheon, and Nicole M Acquisto.
• Department of Data Management, NYC Health + Hospitals/South Brooklyn Health, 2601 Ocean Pkwy, Brooklyn, 11235, NY, USA. Electronic address: treuc@nychhc.org.
• Am J Emerg Med. 2025 Jan 1; 87: 445044-50.

AbstractThe burden of acute bacterial skin and skin structure infections (ABSSSI) continue to plague the healthcare system. One approach to managing moderate-to-severe ABSSSI in low-risk patients involves use of a single dose lipoglycopeptide (LGP), dalbavancin or oritavancin, in the emergency department (ED) and discharge to home with follow-up care. Limited ED studies indicate decreased hospital stays, ED revisits, readmissions, and healthcare costs, as well as improved patient satisfaction with use of these antibiotics. However, existing literature has limitations and gaps, such as insufficient quantifiable data on patient selection criteria, outcome predictors, and risk factors leading to treatment failure. Moreover, there is lack of research on the impact of LGPs on organizational productivity, patient quality of life, and utility in indications beyond ABSSSI. This review focuses on the role of long-acting LGPs in the ED setting for select patients presenting with ABSSSI, aiming to avoid hospitalizations, expedite patient discharge, and prevent readmissions while acknowledging potential limitations of therapy. Additionally, it provides insights into strategies and considerations specifically relevant to implementing this therapeutic approach in the ED.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

19 keywords...

hide…